Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zhibitai Capsules for Primary Hyperlipidemia
NCT06822946Phase 2Completed
- Sponsor
- Chengdu Diao Group Jiuhong Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zhibitai in primary hyperlipidemia, sponsored by Chengdu Diao Group Jiuhong Pharmaceutical. Started Mar 2025; status: completed.
02
Drugs
zhibitai
03
Conditions
primary hyperlipidemia
Beyond the preview
Go deeper on NCT06822946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822946.